RevvityRVTYEarnings & Financial Report
Revvity, Inc. is an American company in the life sciences and diagnostics business that is focused on selling to the pharmaceutical and biotechnology industries, especially in relation to approaches making use of new cell therapy or gene therapy developments. Its origins lie with the long-existing company PerkinElmer, which has been in a variety of business lines.
RVTY Q3 2025 Key Financial Metrics
Revenue
$698.9M
Gross Profit
$374.6M
Operating Profit
$81.9M
Net Profit
$46.7M
Gross Margin
53.6%
Operating Margin
11.7%
Net Margin
6.7%
YoY Growth
2.2%
EPS
$0.40
Financial Flow
Revvity Q3 2025 Financial Summary
Revvity reported revenue of $698.9M for Q3 2025, with a net profit of $46.7M (6.7% margin). Cost of goods sold was $324.3M, operating expenses totaled $292.7M.
Key Financial Metrics
| Total Revenue | $698.9M |
|---|---|
| Net Profit | $46.7M |
| Gross Margin | 53.6% |
| Operating Margin | 11.7% |
| Report Period | Q3 2025 |
Revvity Annual Revenue by Year
Revvity annual revenue history includes year-by-year totals (for example, 2024 revenue was $2.8B).
| Year | Annual Revenue |
|---|---|
| 2024 | $2.8B |
| 2023 | $2.8B |
| 2022 | $4.2B |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $670.7M | $649.9M | $691.7M | $684.0M | $729.4M | $664.8M | $720.3M | $698.9M |
| YoY Growth | -5.8% | -12.3% | 2.5% | -3.5% | 8.7% | 2.3% | 4.1% | 2.2% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $13.42B | $13.43B | $13.42B | $12.77B | $12.39B | $12.36B | $12.36B | $12.14B |
| Liabilities | $5.73B | $5.59B | $5.55B | $4.85B | $4.73B | $4.72B | $4.81B | $4.76B |
| Equity | $7.69B | $7.85B | $7.87B | $7.92B | $7.67B | $7.64B | $7.56B | $7.38B |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $196.6M | $147.6M | $158.6M | $147.9M | $174.2M | $128.2M | $134.3M | $138.5M |
Other Health Care Companies
ABT
Abbott Laboratories
Revenue
$11.4B
Net Profit
$1.6B
BAX
Baxter International
Revenue
$3.0B
Net Profit
$-1.1B
BDX
Becton Dickinson
Revenue
$5.3B
Net Profit
$382.0M
BSX
Boston Scientific
Revenue
$5.3B
Net Profit
$670.0M
DXCM
Dexcom
Revenue
$1.3B
Net Profit
$267.3M
EW
Edwards Lifesciences
Revenue
$1.6B
Net Profit
$291.1M
GEHC
GE HealthCare
Revenue
$5.7B
Net Profit
$588.0M
HOLX
Hologic
Revenue
$1.0B
Net Profit
$179.1M
IDXX
Idexx Laboratories
Revenue
$1.1B
Net Profit
$274.6M
PODD
Insulet Corporation
Revenue
$783.7M
Net Profit
$101.6M